Dr. Alese is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
1365 Clifton Road NE
Atlanta, GA 30322
Education & Training
Emory University School of MedicineFellowship, Hematology and Medical Oncology, 2012 - 2015
Westchester Medical CenterResidency, Internal Medicine, 2009 - 2012
University of IbadanClass of 2000
Certifications & Licensure
GA State Medical License 2013 - 2025- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- Skilled Hands Award
- ASCO International Development and Education Award
- Bethune Round Table
- Join now to see all
Clinical Trials
- Romidepsin in Treating Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Solid Tumors With Liver Dysfunction Start of enrollment: 2012 Jun 12
- An Investigational Immuno-therapy Study of BMS-986205 Given in Combination With Nivolumab and in Combination With Both Nivolumab and Ipilimumab in Cancers That Are Advanced or Have Spread Start of enrollment: 2016 Apr 14
- TAS102 in Combination With NAL-IRI in Advanced GI Cancers Start of enrollment: 2018 Jan 30
- Join now to see all
Publications & Presentations
PubMed
- 45 citationsAdiposity may predict survival in patients with advanced stage cancer treated with immunotherapy in phase 1 clinical trialsDylan J. Martini, Meredith R Kline, Yuan Liu, Julie M. Shabto, Milton Williams
Cancer. 2020-02-01 - 111 citationsThe prognostic and predictive impact of inflammatory biomarkers in patients who have advanced‐stage cancer treated with immunotherapyMehmet Asim Bilen, Dylan J. Martini, Yuan Liu, Colleen Lewis, Hannah Collins
Cancer. 2019-01-01 - 220 citationsImmune checkpoint inhibitors for the treatment of MSI-H/MMR-D colorectal cancer and a perspective on resistance mechanismsIbrahim Halil Sahin, Mehmet Akce, Olatunji B. Alese, Walid L. Shaib, Gregory B. Lesinski
British Journal of Cancer. 2019-10-14
Journal Articles
- A Phase 2 Multi-Institutional Study of Nivolumab for Patients with Advanced Refractory Biliary Tract CancerOlatunji B Alese, Daneng Li, Amit Mahipal, JAMA Oncology
Lectures
- A phase II study of niraparib in combination with EGFR inhibitor panitumumab in patients with advanced colorectal cancer.ASCO Gastrointestinal Cancers Symposium - San Francisco, CA - 1/25/2020
- Perioperative therapy in patients with metastatic colorectal cancer.2019 ASCO Annual Meeting - 6/1/2019
- A phase I/II study of trifluridine/tipiracil (TAS-102) in combination with nanoliposomal irinotecan (NAL-IRI) in advanced GI cancers.2018 ASCO Annual Meeting - Chicago, Illinois - 06/3/2018
Authored Content
- A Phase 2 Multi-Institutional Study of Nivolumab for Patients with Advanced Refractory Biliary Tract CancerMay 2020
- A Phase 2 Multi-Institutional Study of Nivolumab for Patients with Advanced Refractory Biliary Tract CancerMay 2020
Press Mentions
Chronic Stress Speeds Colorectal Cancer’s Spread Dramatically, Study IndicatesOctober 12th, 2024- Rise in Colon Cancer Among Young People, African Americans, Cause for ConcernApril 27th, 2023
- Emory’s Winship Cancer Institute Works to Bridge Racial Disparities in CancerJuly 18th, 2022
- Join now to see all
Grant Support
- Translational Physician-Scientist Training Program in OncologyNational Cancer Institute (NCI)Present
- Nell W. and William Simpson Elkin Cancer Research FellowshipWinship Cancer InstitutePresent
- International Cancer Technology Transfer Fellowship (ICRETT)Union for International Cancer Control (UICC)Present
- Paul Carbone, MD Fellowship GrantEastern Cooperative Oncology Group (ECOG-ACRIN)Present
- Faculty Start-Up Research FundWinship Cancer InstitutePresent
Professional Memberships
- Member
- Member
- Member
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
